Noch viel besser als Calypte: Compumed.
Seite 1 von 2 Neuester Beitrag: 28.10.03 16:39 | ||||
Eröffnet am: | 11.09.03 23:15 | von: kalle4712 | Anzahl Beiträge: | 26 |
Neuester Beitrag: | 28.10.03 16:39 | von: kalle4712 | Leser gesamt: | 2.264 |
Forum: | Hot-Stocks | Leser heute: | 6 | |
Bewertet mit: | ||||
Das Unternehmen entwickelt und vertreibt medizinische Testgeräte. Der Kurs ist heute um 31,25% gestiegen - also deutlich stärker als der von Calypte. Das Kürzel: CMPD.OB.
Na - habt Ihr Lust, bei einer neue Pusher-Aktie ganz am Anfang mit dabei zu sein? Helft alle mit beim Pushen! Vielleicht wird's was!
Der Jahres-Chart sieht nach Untertasse aus. Sehr positiv!
Im Langfrist-Chart erkennt man das mögliche Erholungspotential:
Info lt. yahoo.com: "CompuMed, Inc. is a medical diagnostic product and services company focusing on the diagnosis, monitoring and management of cardiovascular disease and osteoporosis. For the nine months ended 6/30/03, revenues fell 7% to $1.4 million. Net loss fell 50% to $255 thousand. Revenues reflect decreased sales of equipment and supplies. Lower net loss reflects decreased selling expenses, lower SG&A costs and decreased depreciation and amortization expenses."
Real habe ich eine sehr kleine Stückzahl von dieser Aktie. Allerdings habe ich die nicht vor drei Wochen gekauft, sondern schon vor Jahren. Ist eine meiner Depotleichen, die ich auch nicht mehr verfolge.
Der Kurssprung ist mir zufällig ins Auge gefallen. Werde den Anstieg nutzen, um mich zu verabscheiden.
Der Vorteil des Osteogram: Man benötigt nicht viel mehr als einen einfachen PC für die Messung. Damit ist Osteogram wesentlich kostengünstiger als Konkurrenzprodukte. Da das Gesundheitswesen unter Kostendruck steht und Osteoporose nach wie vor auf dem Vormarsch ist, sollte ein beträchtlicher Markt erschließbar sein.
Das Problem. Seit Jahren hat man Probleme mit der Vermarktung. Compumed kommt einfach nicht auf nennenswerte Zuwächse.
Allerdings ist vor ca. einem Jahr ein erfahrener Vertriebsmann eingestellt worden. Kriegt Compumed jetzt die Kurve? Aktuelle Meldungen habe ich leider nicht gefunden.
Ich kann mir aber nicht vorstellen, dass Compumed ohne nennenswerten Hintergrund eine solche Rallye in einem schwachen Marktumfeld hinlegt. Oder gibt es genügend hartgesottene Zocker, die Penny-Stocks auch in fallenden Märkten zum Spielball machen?
Ich schätze, die Aktie könnte Chancen haben, in den Bereich 0,80 bis 0,90 USD vorzudringen. Genügend Schub haben sie ja anscheinend in diesen Tagen. Dann werde ich mich wohl von Compumed verabschieden - oder auch nicht. Warten wir's ab.
CompuMed Signs Licensing and Product Development Agreement With MEDSTRAT
Tuesday October 21, 9:05 am ET
LOS ANGELES, Oct. 21 /PRNewswire-FirstCall/ -- CompuMed, Inc. (OTC Bulletin Board: CMPD - News) -- a medical informatics company serving the healthcare community with diagnostic software solutions -- today announced it has signed a licensing and product development agreement with MEDSTRAT, Inc (Downers Grove, IL), a leading orthopedic imaging informatics company. MEDSTRAT is Fuji Medical's largest U.S. distribution partner in the CR (computed radiography) market. The five-year agreement authorizes MEDSTRAT to package CompuMed's proprietary OsteoGram® system for osteoporosis screening, diagnosis and monitoring with MEDSTRAT's digital imaging system. In addition, the two firms have agreed to cooperate in the development of digital applications specific to the orthopedic market.
The OsteoGram is a software-based computer imaging system that enables healthcare providers to diagnose osteoporosis using a conventional, film-based hand x-ray or a digital image from filmless x-ray equipment. CompuMed recently developed a DICOM compliant version for use on digital imaging platforms, which have become a high growth segment in the medical imaging market.
"We are pleased to announce our association with MEDSTRAT," states CompuMed CEO, Jerry McLaughlin. "The MEDSTRAT digital imaging system represents an excellent marriage of Fuji Medical's SmartCR® (computed radiography) technology and MEDSTRAT's proprietary network server, which come together in a system designed specifically to serve the orthopedic office practice. The OsteoGram application will reside on the MEDSTRAT system, where it will provide orthopedists with the ability to efficiently perform osteoporosis testing within a point-of-care setting. They will also be able to easily move, archive and recall images and reports while eliminating the need for x-ray film and messy chemicals."
The MEDSTRAT digital imaging system includes the Fuji SmartCR® system to offer orthopedic customers a single fully integrated DICOM-based solution. The turnkey package supports HIPAA compliance, and is compatible with most major practice management electronic medical records (EMR) systems. Other digital imaging benefits from the MEDSTRAT system include superior image quality, complete scoliosis views, locally stored images and disaster recovery capabilities.
"In addition to our licensing agreement with MEDSTRAT, we look forward to mutual cooperation in the development of promising new applications that make use of our underlying OsteoGram technology," says McLaughlin. "We are discussing several potential applications that may significantly add to the value of our relationship."
About CompuMed:
Founded in 1973, CompuMed, Inc. (OTC Bulletin Board: CMPD - News) is a leading provider of computer-aided telemedicine and diagnostics technology. The company's core products are the OsteoGram and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The CardioGram also has the capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net or call (310) 258-5000.
About MEDSTRAT
MEDSTRAT is an orthopedic imaging informatics company working with orthopedic practices to implement digital imaging solutions that enable orthopedic physicians to acquire, move, share, archive and secure their valuable data. MEDSTRAT is currently implementing digital solutions across the United States, and has filmless office-based practices all across the country. Practices range in size from solo practitioners to large groups. In addition, MEDSTRAT provides digital imaging services to many professional sports teams. MEDSTRAT currently has 3.2 million images in their database, and adds approximately 48,000 images each week. More information can be found at www.medstrat.com .
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Nein, der Thread ist klasse, alles was das Herz begehrt. Charts mit kurz- und langfristiger Perspektive, Gespür, Fakten. Was will man mehr. Weiterhin ist Compumed seit einer Woche auf 52 Wochen ATH, da werde ich immer hellhörig.
Witerhin ist Dein Balken voll, wer so viel postet, wird wohl was wissen.
An der OTC schaue ich noch nach ISEE, FOTO, TKOCF und son paar anderen. Pavian hat SBIO von der OTC aufgenommen in meinem kleinen US-Wettbewerb. Da gibts ein Eingangsposting zu SBIO.
Oder EXTI von der OTC war in einem Depot, leider sehr kurz.
Dann gibt es den Moneyflow als Kriterium, da schau Dir ruhig mal MTIC! oder TRBO an.
MTIC taucht seit Wochen im Moneyflow auf.
Über EGLS habe ich früher geschrieben, mit Kicky streite? ich mich schon lange über AZPN, was war gestern bei TRBY los?, da darf man mal suchen.
Es gibt viele Ansatzpunkte, um interessante Shares zu finden.
Manchmal werden sie ausführlich vorgestellt, Quadsan hat so einen Qualitätsthread zu IDTA oder CTCH schon früh angefangen, die anderen Freaks aus dem US-Wettbewerb haben auch immer beachtliche Tipps.
Na, man kann viel Gutes auf Ariva lesen, wenn man will.
Gruss E.
21 Oct 2003
Symbol Name Exch Open High Low Close Volume Daily CMF(20)
ADSK Autodesk, Inc. NASD 19.000 19.530 18.890 19.500 1608691 0.203
AZPN Aspen Technology, Inc. NASD 5.820 6.550 5.800 6.540 1070257 0.201
BFLY Bluefly, Inc. NASD 1.940 2.190 1.750 2.090 952651 0.330
BRLI Bio-Reference Laboratories, Inc. NASD 12.500 13.810 12.350 13.800 814567 0.214
CNST Constar International Inc. NASD 5.350 5.590 5.280 5.510 49400 0.228
CPNT Championship Auto Racing NASD 0.500 0.540 0.500 0.540 11700 0.203
CYGX CytoGenix Inc. NASD 0.900 0.920 0.880 0.920 167200 0.238
DCNT Docent, Inc. NASD 4.210 4.750 4.200 4.620 352112 0.202
DTAS Digitas, Inc. NASD 8.650 9.230 8.410 9.040 820151 0.205
EGLS Electroglas, Inc. NASD 2.830 3.450 2.810 3.390 1660737 0.206
GLYN Galyan's Trading Co. NASD 13.040 13.250 12.080 13.000 253292 0.222
LOGI Logitech International S.A. NASD 33.440 41.630 33.200 39.640 1321181 0.266
MOBE Mobility Electronics, Inc. NASD 9.950 10.500 9.830 10.410 1532118 0.205
MTIC MTI Technology Corp. NASD 2.100 2.200 2.060 2.160 206100 0.217
NCEN New Century Financial Corp. NASD 32.490 32.770 31.850 32.720 642520 0.208
NXTI Next, Inc. NASD 1.370 1.410 1.310 1.385 113300 0.226
OCLR Ocular Sciences, Inc. NASD 23.500 25.140 23.500 25.000 172876 0.229
PVTB PrivateBancorp, Inc. NASD 39.450 41.200 39.400 40.300 72860 0.271
RLRN Renaissance Learning, Inc. NASD 24.350 24.600 24.300 24.560 33591 0.267
RSCR Res-Care, Inc. NASD 8.320 8.400 8.140 8.370 434500 0.349
TRBO TurboChef Technologies, Inc. NASD 1.420 1.800 1.380 1.790 359400 0.203
TRBY Torbay Holdings, Inc. NASD 0.011 0.012 0.009 0.011 4138100 0.285
TRMK Trustmark Corp. NASD 28.170 28.240 27.910 28.060 14200 0.217
VDSI VASCO Data Security International, Inc. NASD 3.020 3.150 2.890 3.080 697767 0.322
VION Vion Pharmaceuticals, Inc. NASD 1.830 2.250 1.760 2.250 21861095 0.643
Gruss E.
Nexmed:
http://chart.bigcharts.com/bc3/quickchart/...98&mocktick=1&rand=9274"
Entremed:
http://chart.bigcharts.com/bc3/quickchart/...00&mocktick=1&rand=5929"
Abiomed:
http://chart.bigcharts.com/bc3/quickchart/...93&mocktick=1&rand=9177"
Inamed:
http://chart.bigcharts.com/bc3/quickchart/...43&mocktick=1&rand=8751"
Zu den anderen US-Aktien-Threads: Mir ist schon vor einiger Zeit aufgefallen, dass von Grünspan, DocBroemme, Dir und anderen Teilnehmern Deines Börsenspiels so manch guter Tipp kommt.
Das Handicap: Ich habe nicht soviel Zeit, dass ich ständig auf der Lauer liegen könnte, um schnell reagieren zu können. Und schnell reagieren muss man einfach, wenn man in US-Penny-Stocks investiert. Daher kommen solche Käufe wie Compumed für mich nur in Ausnahmefällen in frage.
Ich konzentriere mich schon seit ca. 1998 auf Small- und MidCaps. Die LargeCaps sind mir einfach zu teuer. Die Chancen sind mir bei LargeCaps aufgrund der naturgemäß nicht mehr sehr hohen Wachstumsraten nicht hoch genug. Ich denke, da sind Small- und MidCaps bei Vermeidung des OTC-Markts ein gesunder Kompromiss.
Übrigens wollte ich heute vormittag auf Deinen USNA-Thread antworten, und zwar auf Deine Frage, ob jemand einen Wert kennt, der in 70 Wochen besser gelaufen ist.
Meine Antwort (mit Chart) ist leider von Ariva zerbombt worden. Daher habe ich es sein lassen.
Die Antwort war: Microstrategy (MSTR). Empfohlen im Herbst 2002 bei 5 USD (splittbereinigt 10:1). Gestern 51,70. Also gute 900%. Deine USNA hat von ca. 8 auf 65 zugelegt, also gut 700%. Sehe ich das richtig so? Oder hast Du schon unter 8 empfohlen. (Ich muss zugeben, dass die Gesamtsteigerung von USNA seit ihrem Tief natürlich wesentlich stärker ist als die von MSTR).
Gruß
Kalle
P.S.: Deine Hinweise werde ich mir gelegentlich mal zu Gemüte führen. Allerdings habe ich nach den Steigerungen der vergangenen Monate noch mehr Bammel, jetzt noch auf den unter Volldampf zockelnden Zug aufzuspringen und weitere OTC-Werte zu kaufen.
Da bleibe ich doch lieber in meinem angestammten Revier.
CompuMed Signs Nationwide Distribution Agreement With NIR
Tuesday October 28, 9:07 am ET
LOS ANGELES, Oct. 28 /PRNewswire-FirstCall/ -- CompuMed, Inc. (OTC Bulletin Board: CMPD - News) -- a medical informatics company serving the healthcare community with diagnostic software solutions -- today announced it has signed a five-year distribution agreement with National Imaging Resources (NIR). Based in Willoughby, Ohio, NIR is one of the largest distribution organizations in the medical imaging field.
ADVERTISEMENT
Under the new agreement, NIR's network of sales representatives will sell CompuMed's patented OsteoGram system to the growing U.S. market for conventional and digital radiography products.
"We are delighted to be associated with NIR and the world-class sales and service professionals that comprise its membership," stated CompuMed CEO, Jerry McLaughlin. "Their focus on selling capital equipment, combined with their commitment to serving the market for digital radiography and PACS network servers, fits nicely with CompuMed's strategy to develop digital medical imaging applications."
The OsteoGram is a software-based computer imaging system that enables healthcare providers to screen, diagnose and monitor osteoporosis using either a conventional, film-based hand x-ray or a digital image from filmless x-ray equipment. CompuMed recently developed a DICOM version for use on digital imaging platforms, which have become a high growth segment of the medical imaging market.
"We believe the OsteoGram can be distributed effectively as a value-added product that will help NIR's reps enhance sales of radiography platforms," added McLaughlin. "Under the new agreement, NIR's customers will be able to upgrade their capital equipment and provide patients with valuable point-of-care osteoporosis testing by using the OsteoGram reimbursement to offset equipment acquisition costs."
About CompuMed:
Founded in 1973, CompuMed, Inc. (OTC Bulletin Board: CMPD - News) is a leading provider of computer-aided telemedicine and diagnostics technology. The company's core products are the OsteoGram and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The CardioGram also has the capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net or call (310) 258-5000.
About NIR
NIR is one of the largest medical equipment sales and service organizations in North America exclusively serving the radiology market. With nearly 200 sales representatives and 500 service engineers covering the 50 United States, Puerto Rico and Caribbean Basin, it is uniquely poised to respond to the ever changing medical imaging needs of it's customers. Total gross sales among NIR members are almost one-half billion dollars. NIR continues to forge strategic alliances with key manufacturers and maintains its position as a world-class capital equipment supplier. For more information, visit www.nirweb.com
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.